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Non-infectious pulmonary complications such as chron-
ic airflow obstruction, bronchiolitis obliterans, bronchi-
olitis obliterans organizing pneumonia, radiation- and
drug-induced lung injuries, diffuse pulmonary hem-
orrhage, and transfusion-related lung injury are well
recognized in leukemia patients who receive high-
dose chemotherapy and supported with hematopoietic
stem cell transplantation (HSCT).1,2 These compli-
cations may cause transient or permanent damage to
the lung parenchyma and pulmonary function changes
in patients who achieve long-term survival. The 
frequently-encountered pulmonary function changes
of non-infectious pulmonary complications after HSCT
include obstructive ventilatory defects, restrictive ven-
tilatory defects, obstructive ventilatory defects with
reduced forced vital capacity (FVC), mixed obstructive
and restrictive ventilatory defects, and reduction in the
diffusing capacity of the lung for carbon monoxide
(DLCO).1,2
For adoption of preventive or therapeutic meas-
ures for those possible pulmonary complications after
HSCT, transplantation oncologists in many institutes
routinely perform pulmonary function studies for stem
cell recipients before and after HSCT even though their
predictive value and clinical usefulness are in doubt.3
Pulmonary function studies encompass spirometry as
well as determination of lung volumes and diffusion
capacity.4–7 Spirometry measures the rate of air exhaled
or inhaled as a function of time.4 The FVC, forced
expiratory volume in the first second (FEV1), and the
FEV1/FVC ratio are the most commonly reported
values. The disproportionate reduction in FEV1/FVC
to below the lower normal limit indicates an obstruc-
tive ventilatory change. The FEV1 is further used to
determine the severity of the obstruction. Total lung
capacity (TLC), residual volume (RV) and vital capac-
ity (VC) are the 3 parameters mainly determined for
lung volumes by most pulmonary function studies.5
A proportional reduction in FEV1/FVC with a re-
duction in TLC confirms the presence of a restrictive
pathologic process. DLCO is a measure of a patient’s
ability to absorb alveolar gases into the capillary blood
flow, which is influenced by alveolar membrane thick-
ness, hematocrit level, cardiac output, and the uneven
distribution of ventilation and perfusion over differ-
ent lung regions.6 A reduction in DLCO is the most
common functional abnormality, and it can be associ-
ated with thoracic irradiation, chemotherapy toxicity,
idiopathic pneumonia, and graft-versus-host disease
(GVHD).
Although pulmonary function studies have been
widely used in HSCT patients, it should be noted that
there are limitations in using the abovementioned tests
to make conclusions in any patient.3,7 A good quality
control program is indispensable in the laboratory where
these pulmonary function tests are performed. This 
is especially critical when serial tests are used for com-
parison in the same patient, i.e. inter- and intraindi-
vidual variation over time. Any reported result must
be generated from a test with a stringent procedure of
merit. Clinicians should be aware that the results of
pulmonary function studies are generally reported as
a percent of predicted normal values. Each laboratory
should have its own reference data or predicted nor-
mal values calculated from a population similar to the
patients to be studied rather than using reference data
generated from a different laboratory or a different
population. The DLCO should also be interpreted
after correction for hemoglobin, which is particularly
important for HSCT patients.
For clarifying the value of using pulmonary function
tests to predict or monitor patients’ lung condition
after HSCT, investigators must recruit a large cohort of
patients for study and utilize both pre-transplant and
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adequate periodical post-transplant data from a labo-
ratory with well-controlled quality.3,7 This, however,
is very difficult to achieve for most investigators. As a
result, 2 studies that had aimed to study the evolutional
change of pulmonary function after HSCT including
DLCO were unable to come to any conclusions.8,9
However, a reduction in DLCO at 2 years was found
to be associated with the presence of chronic GVHD.9
Many other studies have been conducted to determine
if pre-transplant pulmonary function could become a
risk factor for post-transplant pulmonary complications
and, even more, in predicting post-transplant mortality.
The results of most studies agree that pre-transplant
pulmonary compromise is associated with an increase
in post-transplant morbidity.1–4 These results have
prompted transplantation oncologists to perform pul-
monary function tests before and after transplantation.
In this issue of the Journal of the Chinese Medical
Association, Chang et al report a retrospective analysis
of prospectively collected results of pulmonary func-
tion tests including FEV1 and DLCO in context with
clinical data in acute lymphoblastic leukemia patients
who received bone marrow transplantation (BMT)
between August 1983 and February 2005 in a single
institute in Taiwan.10 The strengths of their study 
are: all patients had the same disease and received the
same procedure of BMT; the protocols were homoge-
neous; and patients received pre- and post-transplant
pulmonary function studies longitudinally. Assuming
that the laboratory where the pulmonary function tests
were performed has a good quality control program
and complied with American Thoracic Society recom-
mendations, and with all the results having been care-
fully interpreted by a pulmonologist,4–7 there remain
several issues that need to be addressed. This was a rel-
atively small study, including only 32 patients. Twenty-
three patients were excluded from the original cohort
of 55 patients for the final analysis due to early death
after BMT or not-in-complete-remission status upon
receiving BMT. Unfortunately, the authors did not
report the causes of those early deaths, which could
have been due to either infectious or non-infectious
etiologies. Is it possible that the reduction in DLCO
is just a long-term complication that is only observed
in long-term survivors? Since a significant association
between decreased DLCO and chronic GVHD has been
reported, and GVHD may carry a graft-versus-leukemia
effect, it is possible that DLCO reduction could be 
a consequence of alloreactive activities associated with
a longer survival. The definition of overall survival (OS)
in this study was the interval between diagnosis and
death rather than the interval between BMT and death.
Although in univariate analysis, the authors showed
that months-to-BMT after diagnosis was not a risk
factor for OS, it could still have produced bias in such
a small cohort of patients. What the authors have not
shown in this paper are data on pre-transplant DLCO,
the severity of DLCO reduction in each patient, and
the interval between DLCO reduction and BMT in
each patient.
Over the last decade, peripheral blood stem cell trans-
plantation (PBSCT) has been used more widely than
BMT to treat leukemia patients. Non-myeloablative
HSCT has also been accepted as an alternative to
myeloablative HSCT. It is not known if the data pre-
sented by Chang et al could be applied to acute lym-
phoblastic leukemia patients who receive PBSCT or
non-myeloablative SCT with a variety of different con-
ditioning regimens. Although the information provided
by Chang et al deserves appreciation, it certainly needs
to be validated in a large cohort of patients and, prob-
ably, tested in an animal model.
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